MedTrace Logo

Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

NCT07259889 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-12-02

No results posted yet for this study

Summary

This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.

Conditions

  • Advanced Solid Tumors (Phase 1)

Interventions

DRUG

NK cell preparation

CEL001 injection

Sponsors & Collaborators

  • Guangzhou Xiling Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Ning, Ph.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-16
Primary Completion
2028-06-15
Completion
2028-06-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259889 on ClinicalTrials.gov